CoChat

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

Open access
Cooper, Zachary A., Reuben, Alexandre, Spencer, Christine N., Prieto, Peter A., Austin-Breneman, Jacob L., Jiang, Hong, Haymaker, Cara, Gopalakrishnan, Vancheswaran, Tetzlaff, Michael T., Frederick, Dennie T., Sullivan, Ryan J., Amaria, Rodabe N., Patel, Sapna P., Hwu, Patrick, Woodman, Scott E., Glitza, Isabella C., Diab, Adi, Vence, Luis M., Rodriguez-Canales, Jaime, Parra, Edwin R., Wistuba, Ignacio I., Coussens, Lisa M., Sharpe, Arlene H., Flaherty, Keith T., Gershenwald, Jeffrey E., Chin, Lynda, Davies, Michael A., Clise-Dwyer, Karen, Allison, James P., Sharma, Padmanee, Wargo, Jennifer A. · 2016 · OncoImmunology
Cited by 58

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, and we performed studies to test the hypothesis that clinical patterns and immune infiltrates differ at progression on these treatments. We observed rapid clinical progression kinetics in patients on targeted therapy compared to immune checkpoint blockade. To gain insight into possible immune mechanisms behind these differences, we performed deep immune profiling in tumors of patients on therapy. We demonstrated low CD8+ T-cell infiltrate on targeted therapy and high CD8+ T-cell infiltrate on immune checkpoint blockade at clinical progression. These data have important implications, and suggest that antitumor immune responses should be assessed when considering therapeutic options for patients with melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1136044

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 58

Metadata

Authors
Cooper, Z. A., Reuben, A., Spencer, C. N., Prieto, P. A., Austin-Breneman, J. L., Jiang, H., Haymaker, C., Gopalakrishnan, V., Tetzlaff, M. T., Frederick, D. T., Sullivan, R. J., Amaria, R. N., Patel, S. P., Hwu, P., Woodman, S. E., Glitza, I. C., Diab, A., Vence, L. M., Rodriguez-Canales, J., Parra, E. R., Wistuba, I. I., Coussens, L. M., Sharpe, A. H., Flaherty, K. T., Gershenwald, J. E., Chin, L., Davies, M. A., Clise-Dwyer, K., Allison, J. P., Sharma, P., & Wargo, J. A.
Venue
OncoImmunology
Published
2016-02-02
Volume
5
Issue
3
Pages
e1136044
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2311147682
Cited by
58
References
7
FWCI
4.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. https://app.cochat.ai/papers/10.1080/2162402x.2015.1136044
The paper
Cooper, Z. A., Reuben, A., Spencer, C. N., Prieto, P. A., Austin-Breneman, J. L., Jiang, H., Haymaker, C., Gopalakrishnan, V., Tetzlaff, M. T., Frederick, D. T., Sullivan, R. J., Amaria, R. N., Patel, S. P., Hwu, P., Woodman, S. E., Glitza, I. C., Diab, A., Vence, L. M., Rodriguez-Canales, J., . . . Wargo, J. A. (2016). Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology. https://doi.org/10.1080/2162402x.2015.1136044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.